Vaxart Inc. [VXRT] Is Currently -0.77 below its 200 Period Moving Avg: What Does This Mean?

Related

Vaxart Inc. [NASDAQ: VXRT] loss -0.77% or -0.05 points to close at $6.41 with a heavy trading volume of 3660974 shares. The company report on December 16, 2021 that Vaxart to Test Cross-Reactivity of its COVID-19 Oral Tablet Vaccine Against Omicron.

Cross-reactivity will be assessed using samples from Phase II clinical participants and in a parallel animal challenge study.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored


Oral tablet’s immunogenicity profile suggests it may provide cross-protection against SARS-CoV-2 variants, including Omicron.

It opened the trading session at $6.54, the shares rose to $6.58 and dropped to $6.19, the range by which the price of stock traded the whole day. The daily chart for VXRT points out that the company has recorded -14.42% loss over the past six months. However, it is still -31.89% lower than its most recent low trading price.

If we look at the average trading volume of 3.84M shares, VXRT reached to a volume of 3660974 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here is what top equities market gurus are saying about Vaxart Inc. [VXRT]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for VXRT shares is $13.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on VXRT stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Jefferies have made an estimate for Vaxart Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on December 29, 2021. While these analysts kept the previous recommendation, Cantor Fitzgerald raised their target price to Overweight. The new note on the price target was released on November 02, 2021, representing the official price target for Vaxart Inc. stock. Previously, the target price had yet another drop from $13 to $9, while B. Riley Securities kept a Neutral rating on VXRT stock.

The Average True Range (ATR) for Vaxart Inc. is set at 0.51, with the Price to Sales ratio for VXRT stock in the period of the last 12 months amounting to 671.13. The Price to Book ratio for the last quarter was 3.88, with the Price to Cash per share for the same quarter was set at 1.49.

Trading performance analysis for VXRT stock

Vaxart Inc. [VXRT] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -7.90. With this latest performance, VXRT shares dropped by -15.10% in over the last four-week period, additionally sinking by -14.42% over the last 6 months – not to mention a rise of 12.06% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for VXRT stock in for the last two-week period is set at 44.79, with the RSI for the last a single of trading hit 42.23, and the three-weeks RSI is set at 45.63 for Vaxart Inc. [VXRT]. The present Moving Average for the last 50 days of trading for this stock 6.80, while it was recorded at 6.68 for the last single week of trading, and 7.30 for the last 200 days.

Vaxart Inc. [VXRT]: A deeper dive into fundamental analysis

Operating Margin for any stock indicates how profitable investing would be, and Vaxart Inc. [VXRT] shares currently have an operating margin of -766.66. Vaxart Inc.’s Net Margin is presently recorded at -796.34.

Return on Total Capital for VXRT is now -35.02, given the latest momentum, and Return on Invested Capital for the company is -38.23. Return on Equity for this stock declined to -47.26, with Return on Assets sitting at -33.98. When it comes to the capital structure of this company, Vaxart Inc. [VXRT] has a Total Debt to Total Equity ratio set at 17.94. Additionally, VXRT Total Debt to Total Capital is recorded at 15.21, with Total Debt to Total Assets ending up at 14.51. Long-Term Debt to Equity for the company is recorded at 14.02, with the Long-Term Debt to Total Capital now at 11.89.

Reflecting on the efficiency of the workforce at the company, Vaxart Inc. [VXRT] managed to generate an average of -$1,150,714 per employee. Receivables Turnover for the company is 2.05 with a Total Asset Turnover recorded at a value of 0.04.Vaxart Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 15.30 and a Current Ratio set at 15.30.

>> 7 Top Picks for the Post-Pandemic Economy <<

An analysis of insider ownership at Vaxart Inc. [VXRT]

There are presently around $242 million, or 39.10% of VXRT stock, in the hands of institutional investors. The top three institutional holders of VXRT stocks are: STATE STREET CORP with ownership of 8,632,855, which is approximately 16.083% of the company’s market cap and around 0.71% of the total institutional ownership; BLACKROCK INC., holding 8,095,384 shares of the stock with an approximate value of $52.3 million in VXRT stocks shares; and VANGUARD GROUP INC, currently with $38.67 million in VXRT stock with ownership of nearly 1.963% of the company’s market capitalization.

Positions in Vaxart Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 64 institutional holders increased their position in Vaxart Inc. [NASDAQ:VXRT] by around 4,244,559 shares. Additionally, 55 investors decreased positions by around 1,571,383 shares, while 38 investors held positions by with 31,635,679 shares. The mentioned changes placed institutional holdings at 37,451,621 shares, according to the latest SEC report filing. VXRT stock had 18 new institutional investments in for a total of 505,786 shares, while 17 institutional investors sold positions of 274,341 shares during the same period.